Wednesday, September 07, 2011

Money well spent? Anacor’s Partner GlaxoSmithKline Awarded up to $94 Million in U.S. Government Funding to Support Development of GSK ‘052, a Novel Gram-negative Antibiotic Discovered by Anacor | Business Wire

PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that its partner, GlaxoSmithKline (GSK), has been awarded a contract with the U.S. Department of Health and Human Services’ (HHS) Biomedical Advanced Research and Development Authority (BARDA) to support the ongoing development of GSK2251052 (GSK ‘052, formerly AN3665), a novel boron-based Gram-negative systemic antibiotic discovered by Anacor.

Posted via email from Jack's posterous

No comments: